{
    "clinical_study": {
        "@rank": "30030", 
        "arm_group": [
            {
                "arm_group_label": "755nm Alexandrite Laser", 
                "arm_group_type": "Experimental", 
                "description": "755nm Alexandrite Laser"
            }, 
            {
                "arm_group_label": "Nanosecond 755nm Alexandrite Laser", 
                "arm_group_type": "Experimental", 
                "description": "Nanosecond 755nm Alexandrite Laser"
            }
        ], 
        "brief_summary": {
            "textblock": "Compare the efficacy of the 755nm Alexandrite laser to the nanosecond 755nm Alexandrite\n      laser for the removal of unwanted tattoos using photographic evaluation and histological\n      findings."
        }, 
        "brief_title": "Clinical Evaluation of 755nm Alexandrite Laser Versus Nanosecond 755nm Alexandrite", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": "Tattoos", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Is a healthy male or female between 18 and 85 years old?\n\n          2. Has unwanted non-cosmetic tattoo(s) and wishes to undergo laser treatments\n\n          3. Is willing to consent to participate in the study.\n\n          4. Is willing to shield the tattoo completely from sun exposure\n\n          5. Signs informed consent form\n\n          6. Is willing to comply with all requirements of the study including being photographed,\n             following post treatment care and attending all treatment and follow up visits.\n\n        Exclusion Criteria:\n\n          1. Subjects who are unwilling to consent to tattoos\n\n          2. Subjects mentally ill or incompetent\n\n          3. Subjects is unwilling to have photographs taken and used in publications or\n             scientific presentations\n\n          4. Subjects who are prisoners\n\n          5. Subjects with recent sun exposure and suntan in the area to be treated\n\n          6. Allergic tattoos (hypersensitivity to tattoo ink)\n\n          7. History of vitiligo or keloidal scarring\n\n          8. Tattoos located on the neck or face including cosmetic tattoos\n\n          9. Subjects unwilling to tolerate partial removal of the tattoo in this study\n\n         10. Infection or skin disease in the area to be treated\n\n         11. Subjects who are immunosuppressed (e.g. HIV)\n\n         12. Subject is pregnant or nursing\n\n         13. Use of oral isotretinoin within past 12 months\n\n         14. History of squamous cell carcinoma or melanoma\n\n         15. Is allergic to Lidocaine, tetracaine or Xylocaine with epinephrine.\n\n         16. Has any other reason determined by the physician to be ineligible to participate in\n             the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01811017", 
            "org_study_id": "CYN12-PICO_MGH_TB"
        }, 
        "intervention": {
            "arm_group_label": [
                "755nm Alexandrite Laser", 
                "Nanosecond 755nm Alexandrite Laser"
            ], 
            "description": "755nm Alexandrite Laser", 
            "intervention_name": "755nm Alexandrite Laser", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 3, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02130"
                }, 
                "name": "Boston Va Medical Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "other_outcome": {
            "measure": "Number of participants with adverse events as a measure of safety and tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "up to 3 months post last treatment"
        }, 
        "overall_official": {
            "affiliation": "Cynosure, Inc.", 
            "last_name": "Patricia Krantz", 
            "role": "Study Director"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Photographic Evaluation of Tattoo Clearance", 
            "safety_issue": "No", 
            "time_frame": "up to 3 months post last treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01811017"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Histological evaluation of tissue samples pre-treatment and post-treatment", 
            "measure": "Subject biopsy sampling", 
            "safety_issue": "Yes", 
            "time_frame": "up to 3 months post last treatment"
        }, 
        "source": "Cynosure, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cynosure, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}